1Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHAguideline on the treatment of blood cholesterol to reduceatherosclerotic cardiovascular risk in adults : a report of theAmerican College of Cardiology/ American Heart Association TaskForce on Practice Guidelines [ J] . J Am Coll Cardiol, 2014,63(25 Pt B) :28B9-2934. DOI: 10.1016/j. jacc.2013.11.002.
2Rabar S, Harker M, O'Flynn N, et al. Lipid modification andcardiovascular risk assessment for the primary and secondaryprevention of cardiovascular disease : summary of updated NICEguidance [ J ].BMJ, 2014,349 : g4356.
5Giraldez RR, Giugliano RP, Mohanavelu S, et al. Baseline low-density lipoprotein cholesterol is an important predictor of thebenefit of intensive lipid-lowering therapy: a PROVE IT-TIMI 22(pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22) analysisf J].J Am CollCardiol, 2008,52(11):914-920. DOI: 10. 1016/j. jacc. 2008.05.046.
6Leibowitz M, Karpati T,Cohen-Stavi CJ, et al. Associationbetween achieved low-density lipoprotein levels and major adversecardiac events in patients with stable ischemic heart disease takingstatin treatment [ J ].JAMA Intern Med, 2016,176 ( 8 ) : 1105-1113. DOI: 10.1001/jamaintemmed. 2016. 2751.
